Cambrex, a contract development and manufacturing organisation (CDMO), has partnered with developmental biotechnology firm Eli Lilly to offer improved access to clinical development capabilities. Working with Lilly’s early external innovation and collaboration arm, Lilly Catalyze360-ExploR&D, Cambrex will offer drug substance, product, R&D and analytical service labs to Lilly’s collaborators. Cambrex’s Longmont facility will host the primary services.

Signature Healthcare diverts ambulances amid cyberattack – TechTarget
Signature Healthcare diverts ambulances amid cyberattack TechTarget


